{
  "DOI": "10.1038/s41431-021-00877-y",
  "ISSN": [
    "1018-4813",
    "1476-5438"
  ],
  "URL": "http://dx.doi.org/10.1038/s41431-021-00877-y",
  "abstract": "\u003cjats:title\u003eAbstract\u003c/jats:title\u003e\u003cjats:p\u003eSomatic gene editing (SGE) holds great promise for making genetic therapy possible for many monogenic conditions very soon. Is our current system of European market authorization and reimbursement ready for the expected tsunami of gene therapies? At a recent workshop of the Netherlands ZonMw consortium on ethical, legal, and social implications of personalized medicine, we discussed the current possibilities for bringing new gene therapies to the clinic. In Europe, it is not yet clear whether the route via the European medicines agency as an advanced therapy medicinal product is the most appropriate for evaluation of highly personalized SGE applications, although this may optimally guarantee safety and effectiveness. Compassionate use may ensure faster access than the centralized procedure but does not stimulate the commercial development of products. Prescription to named patients may only provide adequate access for single patients. Temporary authorization of use may allow access to medication half a year before formal market authorization has been granted, but may also have large budget impacts. Magistral compounding under a hospital exemption may be an attractive solution for rare, tailor-made applications at an acceptable price. To approve local experimental use of a therapy on a case-by-case basis may be fast, but does not guarantee optimal safety, effectiveness, and broad implementation. We argue that alternative routes should be considered for products developed for a market of large groups of patients versus unique personalized treatments. A balance between scientific evidence for safety and effectiveness, affordability, and fast access may demand a range of alternative solutions.\u003c/jats:p\u003e",
  "alternative-id": [
    "877"
  ],
  "assertion": [
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "Received",
      "name": "received",
      "order": 1,
      "value": "17 December 2020"
    },
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "Revised",
      "name": "revised",
      "order": 2,
      "value": "16 March 2021"
    },
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "Accepted",
      "name": "accepted",
      "order": 3,
      "value": "19 March 2021"
    },
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "First Online",
      "name": "first_online",
      "order": 4,
      "value": "14 April 2021"
    },
    {
      "group": {
        "label": "Compliance with ethical standards",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 1
    },
    {
      "group": {
        "label": "Ethical approval",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 2,
      "value": "The Medical Ethical Committee of VU University Medical Center Amsterdam considered the study exempt from the Law Medical Scientific Research (decision #2018.455, 6 September 2018). All participants signed an informed consent form prior to the meeting."
    },
    {
      "group": {
        "label": "Conflict of interest",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 3,
      "value": "The authors declare that they have no conflict of interest. The views expressed in this article are the personal views of the authors and may not be understood nor quoted as being made on behalf of, or reflecting the position of the National Health Care Institute."
    }
  ],
  "author": [
    {
      "affiliation": [],
      "family": "Rigter",
      "given": "Tessel",
      "sequence": "first"
    },
    {
      "ORCID": "http://orcid.org/0000-0003-0235-4665",
      "affiliation": [],
      "authenticated-orcid": false,
      "family": "Klein",
      "given": "David",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Weinreich",
      "given": "Stephanie S.",
      "sequence": "additional"
    },
    {
      "ORCID": "http://orcid.org/0000-0002-5397-5544",
      "affiliation": [],
      "authenticated-orcid": false,
      "family": "Cornel",
      "given": "Martina C.",
      "sequence": "additional"
    }
  ],
  "container-title": [
    "European Journal of Human Genetics"
  ],
  "content-domain": {
    "crossmark-restriction": false,
    "domain": [
      "link.springer.com"
    ]
  },
  "created": {
    "date-parts": [
      [
        2021,
        4,
        14
      ]
    ],
    "date-time": "2021-04-14T01:02:41Z",
    "timestamp": 1618362161000
  },
  "deposited": {
    "date-parts": [
      [
        2021,
        10,
        1
      ]
    ],
    "date-time": "2021-10-01T04:08:19Z",
    "timestamp": 1633061299000
  },
  "funder": [
    {
      "DOI": "10.13039/501100001826",
      "award": [
        "846003102",
        "846003102"
      ],
      "doi-asserted-by": "publisher",
      "name": "ZonMw"
    }
  ],
  "indexed": {
    "date-parts": [
      [
        2024,
        2,
        4
      ]
    ],
    "date-time": "2024-02-04T21:07:03Z",
    "timestamp": 1707080823193
  },
  "is-referenced-by-count": 8,
  "issn-type": [
    {
      "type": "print",
      "value": "1018-4813"
    },
    {
      "type": "electronic",
      "value": "1476-5438"
    }
  ],
  "issue": "10",
  "issued": {
    "date-parts": [
      [
        2021,
        4,
        14
      ]
    ]
  },
  "journal-issue": {
    "issue": "10",
    "published-print": {
      "date-parts": [
        [
          2021,
          10
        ]
      ]
    }
  },
  "language": "en",
  "license": [
    {
      "URL": "https://creativecommons.org/licenses/by/4.0",
      "content-version": "tdm",
      "delay-in-days": 0,
      "start": {
        "date-parts": [
          [
            2021,
            4,
            14
          ]
        ],
        "date-time": "2021-04-14T00:00:00Z",
        "timestamp": 1618358400000
      }
    },
    {
      "URL": "https://creativecommons.org/licenses/by/4.0",
      "content-version": "vor",
      "delay-in-days": 0,
      "start": {
        "date-parts": [
          [
            2021,
            4,
            14
          ]
        ],
        "date-time": "2021-04-14T00:00:00Z",
        "timestamp": 1618358400000
      }
    }
  ],
  "link": [
    {
      "URL": "https://www.nature.com/articles/s41431-021-00877-y.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "https://www.nature.com/articles/s41431-021-00877-y",
      "content-type": "text/html",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "https://www.nature.com/articles/s41431-021-00877-y.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "similarity-checking"
    }
  ],
  "member": "297",
  "page": "1477-1484",
  "prefix": "10.1038",
  "published": {
    "date-parts": [
      [
        2021,
        4,
        14
      ]
    ]
  },
  "published-online": {
    "date-parts": [
      [
        2021,
        4,
        14
      ]
    ]
  },
  "published-print": {
    "date-parts": [
      [
        2021,
        10
      ]
    ]
  },
  "publisher": "Springer Science and Business Media LLC",
  "reference": [
    {
      "DOI": "10.1038/s41586-020-1978-5",
      "author": "JA Doudna",
      "doi-asserted-by": "publisher",
      "first-page": "229",
      "journal-title": "Nature",
      "key": "877_CR1",
      "unstructured": "Doudna JA. The promise and challenge of therapeutic genome editing. Nature. 2020;578:229–36.",
      "volume": "578",
      "year": "2020"
    },
    {
      "DOI": "10.1038/s41431-018-0309-x",
      "author": "MC Cornel",
      "doi-asserted-by": "publisher",
      "first-page": "484",
      "journal-title": "Eur J Hum Genet",
      "key": "877_CR2",
      "unstructured": "Cornel MC, Howard HC, Lim D, Bonham VL, Wartiovaara K. Moving towards a cure in genetics: what is needed to bring somatic gene therapy to the clinic? Eur J Hum Genet. 2019;27:484–7.",
      "volume": "27",
      "year": "2019"
    },
    {
      "DOI": "10.1021/acs.accounts.9b00106",
      "author": "D Wilbie",
      "doi-asserted-by": "publisher",
      "first-page": "1555",
      "journal-title": "Acc Chem Res",
      "key": "877_CR3",
      "unstructured": "Wilbie D, Walther J, Mastrobattista E. Delivery aspects of CRISPR/Cas for in vivo genome editing. Acc Chem Res. 2019;52:1555–64.",
      "volume": "52",
      "year": "2019"
    },
    {
      "DOI": "10.1002/cpt.1617",
      "author": "T Teixeira",
      "doi-asserted-by": "publisher",
      "first-page": "507",
      "journal-title": "Clin Pharmacol Therap",
      "key": "877_CR4",
      "unstructured": "Teixeira T, Kweder SL, Saint-Raymond A. Are the European medicines agency, US food and drug administration, and other international regulators talking to each other? Clin Pharmacol Therap. 2020;107:507–13.",
      "volume": "107",
      "year": "2020"
    },
    {
      "key": "877_CR5",
      "unstructured": "European Medicines Agency (EMA). Orphan designation: overview. June, 2020. https://www.ema.europa.eu/en/human-regulatory/overview/orphan-designation-overview."
    },
    {
      "key": "877_CR6",
      "unstructured": "Vertex Pharmaceuticals Incorporated. A safety and efficacy study evaluating CTX001 in subjects with severe sickle cell disease. 2018. https://ClinicalTrials.gov/show/NCT03745287."
    },
    {
      "key": "877_CR7",
      "unstructured": "Gupta Strategists. The cost of opportunity: a study on pharmaceutical R\u0026D costs. 2019. https://gupta-strategists.nl/storage/files/The-cost-of-opportunity-Gupta-Strategists.pdf."
    },
    {
      "DOI": "10.1186/s13023-019-1246-7",
      "author": "J Mestre-Ferrandiz",
      "doi-asserted-by": "publisher",
      "journal-title": "Orphanet J Rare Dis",
      "key": "877_CR8",
      "unstructured": "Mestre-Ferrandiz J, Palaska C, Kelly T, Hutchings A, Parnaby A. An analysis of orphan medicine expenditure in Europe: is it sustainable? Orphanet J Rare Dis. 2019;14:287.",
      "volume": "14",
      "year": "2019"
    },
    {
      "key": "877_CR9",
      "unstructured": "European Medicines Agency (EMA). Applications for new human medicines under evaluation by the Committee for Medicinal Products for Human Use. 2021; March. https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-january-2021_en.pdf."
    },
    {
      "key": "877_CR10",
      "unstructured": "European Medicines Agency (EMA). Advanced therapy medicinal products: overview. April 2020. https://www.ema.europa.eu/en/human-regulatory/overview/advanced-therapy-medicinal-products-overview."
    },
    {
      "DOI": "10.1038/s41431-020-0607-y",
      "author": "M Mourby",
      "doi-asserted-by": "publisher",
      "first-page": "979",
      "journal-title": "Eur J Hum Genet",
      "key": "877_CR11",
      "unstructured": "Mourby M, Morrison M. Gene therapy regulation: could in-body editing fall through the net? Eur J Hum Genet. 2020;28:979–81.",
      "volume": "28",
      "year": "2020"
    },
    {
      "key": "877_CR12",
      "unstructured": "European Medicines Agency (EMA). Yescarta. European public assessment report. 2018; May. https://www.ema.europa.eu/en/documents/assessment-report/yescarta-epar-public-assessment-report_en.pdf."
    },
    {
      "key": "877_CR13",
      "unstructured": "Zorginstituut Nederland [National Health Care Institute]. Pakketadvies voretigene neparvovec (Luxturna®) bij de behandeling van visusverlies door erfelijke retinale dystrofie met bi-allelische RPE65-mutaties. December 2020. https://www.zorginstituutnederland.nl/publicaties/adviezen/2020/02/17/pakketadvies-voretigene-neparvovec-luxturna."
    },
    {
      "key": "877_CR14",
      "unstructured": "Hesselgrave B Zolgensma: The $2.1 million drug. Drug Topics. 2019; April 2020; 163. https://www.drugtopics.com/drug-price/zolgensma-21-million-drug."
    },
    {
      "key": "877_CR15",
      "unstructured": "European Medicines Agency (EMA). New gene therapy to treat spinal muscular atrophy [press release]. 2020. https://www.ema.europa.eu/en/news/new-gene-therapy-treat-spinal-muscular-atrophy-corrected."
    },
    {
      "DOI": "10.1016/j.jval.2017.10.015",
      "author": "M Schlander",
      "doi-asserted-by": "publisher",
      "first-page": "525",
      "journal-title": "Value Health",
      "key": "877_CR16",
      "unstructured": "Schlander M, Dintsios CM, Gandjour A. budgetary impact and cost drivers of drugs for rare and ultrarare diseases. Value Health. 2018;21:525–31.",
      "volume": "21",
      "year": "2018"
    },
    {
      "key": "877_CR17",
      "unstructured": "Grant K. Canadian parents of babies with rare deadly disease look to Novartis treatment lottery. The Globe and Mail. 2020. https://www.theglobeandmail.com/canada/article-parents-of-babies-with-deadly-rare-disease-desperate-to-win-drug-maker/."
    },
    {
      "author": "JA Roscamp",
      "first-page": "1",
      "journal-title": "Rheumatology",
      "key": "877_CR18",
      "unstructured": "Roscamp JA, D’Cruz DP. The funding lottery for potentially life-threatening rare diseases. Rheumatology. 2017;57:1–2.",
      "volume": "57",
      "year": "2017"
    },
    {
      "key": "877_CR19",
      "unstructured": "Health and Youth Care Inspectorate of the Ministry of Health, Welfare and Sport (the Netherlands). Supply of unregistered pharmaceutical products: FAQ’s. 2018; May 2020. https://english.igj.nl/documents/publication/2017/07/21/supply-of-unregistered-pharmaceutical-products-faqs."
    },
    {
      "DOI": "10.1186/s13023-019-1026-4",
      "author": "M Bourdoncle",
      "doi-asserted-by": "publisher",
      "journal-title": "Orphanet J Rare Dis",
      "key": "877_CR20",
      "unstructured": "Bourdoncle M, Juillard-Condat B, Taboulet F. Patient access to orphan drugs in France. Orphanet J Rare Dis. 2019;14:47.",
      "volume": "14",
      "year": "2019"
    },
    {
      "key": "877_CR21",
      "unstructured": "Haering M. French early access compassionate use program ATU: still an eternal flame? 2019."
    },
    {
      "key": "877_CR22",
      "unstructured": "Agence Nationale De Sécurité du Médicament et des Produits de Santé (ANSM). Notice to applicants for marketing for temporary authorisation for use (ATU). 2015. p. 4."
    },
    {
      "DOI": "10.1182/blood-2017-03-774174",
      "author": "P Rio",
      "doi-asserted-by": "publisher",
      "first-page": "1535",
      "journal-title": "Blood",
      "key": "877_CR23",
      "unstructured": "Rio P, Navarro S, Guenechea G, Sanchez-Dominguez R, Lamana ML, Yanez R. et al. Engraftment and in vivo proliferation advantage of gene-corrected mobilized CD34(+) cells from Fanconi anemia patients. Blood. 2017;130:1535–42.",
      "volume": "130",
      "year": "2017"
    },
    {
      "DOI": "10.1056/NEJMoa1813279",
      "author": "J Kim",
      "doi-asserted-by": "publisher",
      "first-page": "1644",
      "journal-title": "N Engl J Med",
      "key": "877_CR24",
      "unstructured": "Kim J, Hu C, Moufawad El Achkar C, Black LE, Douville J, Larson A, et al. Patient-customized oligonucleotide therapy for a rare genetic disease. N Engl J Med. 2019;381:1644–52.",
      "volume": "381",
      "year": "2019"
    },
    {
      "key": "877_CR25",
      "unstructured": "Ministerie van Volksgezondheid, Welzijn en Sport [Ministry of Health, Welfare and Sport]. Besluit van 1 oktober 2019, houdende wijziging van het besluit zorgverzekering in verband met het zorgpakket Zvw. 2020. stb-2019-314 ed2019. https://zoek.officielebekendmakingen.nl/stb-2019-314.html."
    },
    {
      "author": "P Meij",
      "first-page": "2020",
      "issue": "May",
      "journal-title": "Brief Pap",
      "key": "877_CR26",
      "unstructured": "Meij P, Canals JM, Scott M. Advances therapy medicinal products. Brief Pap. 2019;3(May):2020. LERU [Internet]",
      "volume": "3",
      "year": "2019"
    },
    {
      "key": "877_CR27",
      "unstructured": "Bisnajak A. The design of a small-scale manufacturing unit for personalized medicine production. Delft University of Technology. 2018."
    },
    {
      "key": "877_CR28",
      "unstructured": "Zorg Instituut Nederland (ZIN) [Dutch National Healthcare Institute]. Advising on and clarifying the contents of the standard health care benefit package. April 2020. https://english.zorginstituutnederland.nl/about-us/tasks-of-the-national-health-care-institute/advising-on-and-clarifying-the-contents-of-the-standard-health-care-benefit-package."
    },
    {
      "DOI": "10.1186/s13023-017-0636-y",
      "author": "SS Weinreich",
      "doi-asserted-by": "publisher",
      "journal-title": "Orphanet J Rare Dis",
      "key": "877_CR29",
      "unstructured": "Weinreich SS, Vrinten C, Kuijpers MR, Lipka AF, Schimmel KJM, van Zwet EW, et al. Aggregated N-of-1 trials for unlicensed medicines for small populations: an assessment of a trial with ephedrine for myasthenia gravis. Orphanet J Rare Dis. 2017;12:88.",
      "volume": "12",
      "year": "2017"
    },
    {
      "DOI": "10.1080/20016689.2020.1715536",
      "author": "J Jørgensen",
      "doi-asserted-by": "publisher",
      "first-page": "1715536",
      "journal-title": "J Mark Access Health Policy",
      "key": "877_CR30",
      "unstructured": "Jørgensen J, Hanna E, Kefalas P. Outcomes-based reimbursement for gene therapies in practice: the experience of recently launched CAR-T cell therapies in major European countries. J Mark Access Health Policy. 2020;8:1715536.",
      "volume": "8",
      "year": "2020"
    },
    {
      "key": "877_CR31",
      "unstructured": "Cosset D, Legros C, Haugen J, Meddeb L. ATU in France: the case for early consideration in local and european P\u0026MA strategy. Simon Kucher \u0026 Partners. 2020. Available from: https://www.simon-kucher.com/nl/node/5099."
    },
    {
      "DOI": "10.1136/bmj.m401",
      "author": "T Sheldon",
      "doi-asserted-by": "publisher",
      "first-page": "m401",
      "journal-title": "BMJ",
      "key": "877_CR32",
      "unstructured": "Sheldon T. Dutch hospital resumes production of rare drug after sourcing purer ingredients. BMJ. 2020;368:m401.",
      "volume": "368",
      "year": "2020"
    },
    {
      "key": "877_CR33",
      "unstructured": "European Association of Hospital Pharmacists (EAHP). Compounding. 2019; April 2020. https://www.eahp.eu/practice-and-policy/compounding."
    },
    {
      "key": "877_CR34",
      "unstructured": "Health and Youth Care Inspectorate of the Ministry of Health, Welfare and Sport (The Netherlands). Vragen en antwoorden over de hospital exemption voor ATMP’s [Questions and answers about the hospital exemption for ATMPs]. 2010; April 2020. https://www.igj.nl/zorgsectoren/geneesmiddelen/documenten/publicaties/2010/08/05/vragen-en-antwoorden-over-de-hospital-exemption-voor-atmp%E2%80%99s."
    }
  ],
  "reference-count": 34,
  "references-count": 34,
  "resource": {
    "primary": {
      "URL": "https://www.nature.com/articles/s41431-021-00877-y"
    }
  },
  "score": 0,
  "short-container-title": [
    "Eur J Hum Genet"
  ],
  "source": "Crossref",
  "title": [
    "Moving somatic gene editing to the clinic: routes to market access and reimbursement in Europe"
  ],
  "type": "journal-article",
  "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy",
  "volume": "29"
}